Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
Centre Hospitalier Universitaire, Amiens
300 participants
Mar 11, 2021
OBSERVATIONAL
Conditions
Summary
Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications. The movement to oral oncology medications has altered the balance of risks and adverse effects (AEs) in the treatment of cancer care. These treatments are associated with a different constellation of AEs and drug interactions. Patients receiving treatment with oral anticancer treatment (OAT) encounter several barriers to adherence, which may include limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. The purpose of this study is to evaluate the drug adherence in cancer patients, using the medication possession ratio (MPR), before and after the implementation of a multidisciplinary consultation program (MCP), on initiation of OAT.
Eligibility
Inclusion Criteria1
- French speaking patients with a newly diagnosed or relapsed cancer, regardless of location and introduction of oral anticancer treatment
Exclusion Criteria3
- patients treated with hormone therapy only
- Patient with severe psychiatric disorders
- patient who does not speak the French language
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04797143